# Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05503888/  
OnCo record `nct05503888` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of aumolertinib and retlirafusp alfa in lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., not yet recruiting.

## Summary

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer is a phase 1/2, randomised interventional study registered as NCT05503888 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with a registry enrolment figure of 160 participants, started 2022-10-01 and due to reach its primary completion in 2027-07-30. Interventions recorded: Almonertinib combined with SHR-1701; Almonertinib. Conditions listed: Relapsed or Advanced Non-small Cell Lung Cancer. Primary outcome: Dose limiting toxicity （Phase Ib）; The incidence and severity of ≥ grade 3 treatment-related adverse events (TRAE) and serious adverse events (TRSAE) in the combination of two drugs （Phase Ib）; PFS rate at 12 months. Lung eligibility wording from the registry: "Advanced NSCLC diagnosed by histology or cytology, or recurrent NSCLC after radical treatment such as surgery, radiotherapy, chemoradiotherapy". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05503888
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Clinical Study of Almonertinib Combined With SHR-1701 or Other Innovative Drugs in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer With EGFR Mutation
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT05503888: https://clinicaltrials.gov/study/NCT05503888

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/), [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05503888.json